Zolbetuximab
Anti-CLDN18.2 monoclonal antibody
An antibody targeting CLDN18.2 in stomach and gastro-oesophageal junction cancer.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
- Generic name
- zolbetuximab
- Other names
- claudiximab, IMAB362
- Route
- Intravenous infusion
- Drug class
- Anti-CLDN18.2 monoclonal antibody
Registration status
Registration status and availability in Indonesia must be confirmed directly with the health facility or authorized distributor. This page is not a source of marketing approval status.
Not a marketing-authorisation source
TanyaKanker does not state a drug's marketing approval status in Indonesia. Confirm official status only through a healthcare facility, BPOM, or an authorised distributor.
Access considerations
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
What needs verification
- Indications approved in the country where the drug is used.
- Compliance with the patient's latest biological marker examination results.
- Plan to monitor side effects and interactions with other drugs being used.
Related
Sources
- NCI Drug Dictionary(lembaga)
Studies related to this drug marker
NCT07872722Phase 2Combination regimen
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Stomach Cancer | biomarker: CLDN18.2 | Immunotherapy, Targeted therapy, Chemotherapy
Japan4 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker CLDN18.2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07872722Not verified
Request cost and access questions
We prepare cost and availability questions that need direct confirmation from a facility.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- CLDN18.2
Biomarker
Reason: Targets this marker
- Targeted therapy
Treatment category
Reason: Uses this drug
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Clinical trial
Reason: Uses this drug
- Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Clinical trial
Reason: Uses this drug
- Gastric cancer after chemotherapy no longer gives results
Decision situation
Reason: Related to this page
- CLDN18.2 positive (75 percent or more, 2+ intensity or higher)
Molecular alteration
Reason: Related to this page
To check
- Cost and access questions
Tool
Reason: Prepare questions to ask a facility
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Complete pathway
CLDN18.2 in stomach cancer
A CLDN18.2 result is positive. What does it mean and what is worth discussing with the medical team?
- CLDN18.2 markerStarting point: what this marker shows and what it does not decide by itself.
- CLDN18.2 positiveWhat a positive result means under the pathology testing threshold.
- CLDN18.2 IHCA common testing method, including on stored tissue blocks.
- After chemotherapy stops workingThe decision situation when first-line therapy no longer controls the disease.
- ZolbetuximabAn anti-CLDN18.2 therapy approved in several countries and given with chemotherapy.
- Positive CLDN18.2 result guideMeaning of the result, approved options versus investigational ones, and questions for the doctor.
A structured summary so IHC results and treatment history are readable.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.